Literature DB >> 18838175

DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype.

Nina Movsesyan1, Mikayel Mkrtichyan, Irina Petrushina, Ted M Ross, David H Cribbs, Michael G Agadjanyan, Anahit Ghochikyan.   

Abstract

We have engineered a DNA epitope vaccine that expresses 3 self-B cell epitopes of Abeta(42) (3Abeta(1-11)), a non-self T helper (Th) cell epitope (PADRE), and 3 copies of C3d (3C3d), a component of complement as a molecular adjuvant, designed to safely reduce CNS Abeta. Immunization of mice with 3Abeta(1-11)-PADRE epitope vaccine alone generated only moderate levels of anti-Abeta antibodies and a pro-inflammatory T helper (Th1 phenotype) cellular immune response. However, the addition of 3C3d to the vaccine construct significantly augmented the anti-Abeta humoral immune response and, importantly, shifted the cellular immune response towards the potentially safer anti-inflammatory Th2 phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838175      PMCID: PMC2637203          DOI: 10.1016/j.jneuroim.2008.08.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  46 in total

Review 1.  Innate immunity--beginning to fulfill its promise?

Authors:  D T Fearon
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

2.  The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts.

Authors:  A Cherukuri; P C Cheng; H W Sohn; S K Pierce
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

3.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

4.  C3d enhanced DNA vaccination induced humoral immune response to glycoprotein C of pseudorabies virus.

Authors:  Tiezhu Tong; Huiying Fan; Yadi Tan; Shaobo Xiao; Jieyu Ling; Huanchun Chen; Aizhen Guo
Journal:  Biochem Biophys Res Commun       Date:  2006-05-23       Impact factor: 3.575

5.  Interleukin 12 induces crescentic glomerular lesions in a high IgA strain of ddY mice, independently of changes in IgA deposition.

Authors:  F Nogaki; E Muso; I Kobayashi; H Kusano; K Shirakawa; T Kamata; A Oyama; T Ono; S Miyawaki; H Yoshida; S Sasayama
Journal:  Nephrol Dial Transplant       Date:  2000-08       Impact factor: 5.992

6.  Abeta species removal after abeta42 immunization.

Authors:  James A R Nicoll; Edward Barton; Delphine Boche; Jim W Neal; Isidro Ferrer; Petrina Thompson; Christina Vlachouli; David Wilkinson; Antony Bayer; Dora Games; Peter Seubert; Dale Schenk; Clive Holmes
Journal:  J Neuropathol Exp Neurol       Date:  2006-11       Impact factor: 3.685

7.  Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.

Authors:  Irina Petrushina; Anahit Ghochikyan; Mikayel Mktrichyan; Gregory Mamikonyan; Nina Movsesyan; Hayk Davtyan; Archita Patel; Elizabeth Head; David H Cribbs; Michael G Agadjanyan
Journal:  J Neurosci       Date:  2007-11-14       Impact factor: 6.167

8.  Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

Authors:  Clive Holmes; Delphine Boche; David Wilkinson; Ghasem Yadegarfar; Vivienne Hopkins; Anthony Bayer; Roy W Jones; Roger Bullock; Seth Love; James W Neal; Elina Zotova; James A R Nicoll
Journal:  Lancet       Date:  2008-07-19       Impact factor: 79.321

9.  Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers.

Authors:  Grigor Mamikonyan; Mihaela Necula; Mikayel Mkrtichyan; Anahit Ghochikyan; Irina Petrushina; Nina Movsesyan; Erene Mina; Anatoly Kiyatkin; Charles G Glabe; David H Cribbs; Michael G Agadjanyan
Journal:  J Biol Chem       Date:  2007-06-01       Impact factor: 5.157

10.  Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid.

Authors:  Guiquan Chen; Karen S Chen; Dione Kobayashi; Robin Barbour; Ruth Motter; Dora Games; Stephen J Martin; Richard G M Morris
Journal:  J Neurosci       Date:  2007-03-07       Impact factor: 6.167

View more
  16 in total

1.  Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.

Authors:  Nina Movsesyan; Hayk Davtyan; Mikayel Mkrtichyan; Irina Petrushina; Tigran Tiraturyan; Ted Ross; Michael G Agadjanyan; Anahit Ghochikyan; David H Cribbs
Journal:  Hum Gene Ther       Date:  2010-11       Impact factor: 5.695

2.  DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Larry D Anderson; Olaf Stüve; Todd N Eagar; Roger N Rosenberg
Journal:  Cell Mol Neurobiol       Date:  2011-04-06       Impact factor: 5.046

Review 3.  Amyloid-beta immunotherapy for Alzheimer's disease.

Authors:  H J Fu; B Liu; J L Frost; C A Lemere
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 4.  Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Authors:  David H Cribbs
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

5.  MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency.

Authors:  Hayk Davtyan; Karen Zagorski; Irina Petrushina; Konstantin Kazarian; Natalie R S Goldberg; Janet Petrosyan; Mathew Blurton-Jones; Eliezer Masliah; David H Cribbs; Michael G Agadjanyan; Anahit Ghochikyan
Journal:  Neurobiol Aging       Date:  2017-08-10       Impact factor: 4.673

6.  Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.

Authors:  Bao-Xi Qu; Doris Lambracht-Washington; Min Fu; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal:  Vaccine       Date:  2010-06-04       Impact factor: 3.641

7.  Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Irina Petrushina; Armine Hovakimyan; Arpine Davtyan; Anna Poghosyan; Annette M Marleau; Nina Movsesyan; Anatoly Kiyatkin; Suhail Rasool; Anna Kirstine Larsen; Peter Juul Madsen; Karen Malene Wegener; Dorte Kornerup Ditlevsen; David H Cribbs; Lars Ostergaard Pedersen; Michael G Agadjanyan
Journal:  J Neurosci       Date:  2013-03-13       Impact factor: 6.167

8.  DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Authors:  H Davtyan; M Mkrtichyan; N Movsesyan; I Petrushina; G Mamikonyan; D H Cribbs; M G Agadjanyan; A Ghochikyan
Journal:  Gene Ther       Date:  2009-10-29       Impact factor: 5.250

9.  Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.

Authors:  Anahit Ghochikyan; Hayk Davtyan; Irina Petrushina; Armine Hovakimyan; Nina Movsesyan; Arpine Davtyan; Anatoly Kiyatkin; David H Cribbs; Michael G Agadjanyan
Journal:  Hum Vaccin Immunother       Date:  2013-02-11       Impact factor: 3.452

10.  Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques.

Authors:  Claire F Evans; Hayk Davtyan; Irina Petrushina; Armine Hovakimyan; Arpine Davtyan; Drew Hannaman; David H Cribbs; Michael G Agadjanyan; Anahit Ghochikyan
Journal:  Alzheimers Dement       Date:  2013-07-31       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.